Comparative Pharmacology
Head-to-head clinical analysis: MORPHINE SULFATE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MORPHINE SULFATE versus QDOLO.
MORPHINE SULFATE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at mu, kappa, and delta opioid receptors in the central nervous system, mimicking endogenous endorphins. Primarily mu-receptor activation leads to analgesia by inhibiting adenylate cyclase, decreasing cAMP, and modulating ion channels (e.g., opening GIRK channels, closing voltage-gated calcium channels), reducing neurotransmitter release.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
5-10 mg intravenously every 4 hours as needed; 10-30 mg orally every 4 hours as needed; 0.1-0.2 mg/kg intramuscularly every 4 hours as needed.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (6-8 hours), elderly, and renal impairment (up to 15 hours).
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 90% (primarily as morphine-3-glucuronide and morphine-6-glucuronide, with 10% unchanged); Biliary/Fecal: 7-10%.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist